Philips and Illumina Team Up with Navican, an Intermountain Healthcare Company, to Accelerate the Delivery of Precision Medicine to Health Systems Worldwide

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) and Navican, an Intermountain Healthcare company, today signed an agreement to deploy a precision health informatics solution that will allow hospitals and health systems worldwide to access the sophisticated services of Intermountain's successful precision medicine program in a "turn-key" manner. The new services, that will be made available through Navican, are aimed at improving outcomes for late stage cancer patients and will offer specialized programs with expert guidance for both oncologists and patients.

The new solution will leverage Navican’s TheraMap Precision Cancer CareTM services and Philips IntelliSpace Genomics platform that integrates large-scale genomic analysis with extensive contextual clinical patient data and that is built to implement precision medicine programs at the point of care. The Philips platform seamlessly integrates Illumina’s next-generation sequencing technologies.

"Despite major technological advances in tumor sequencing capabilities and laboratories, gaps remain between these advanced diagnostics and actually getting patients onto the appropriate therapeutic paths," says Lincoln Nadauld, MD, PhD, executive director of Intermountain Precision Genomics. "Through this joint approach we are bringing together the latest technologies with the aim to provide community hospitals and treatment centers worldwide with the opportunity to implement Intermountain's best practice in precision medicine into their everyday care practices."

Nationally leading precision cancer genomics program
Intermountain Healthcare - a Utah-based, Integrated Delivery Network comprised of 22 hospitals and 180 clinics - provides a nationally leading precision cancer genomics program through its Intermountain Precision Genomics laboratory. The genetic makeup of each patient's cancer is analyzed. Then a team of skilled molecular tumor specialists and specialized treatment navigators is employed to review each test and determine how to most effectively treat that cancer case. This team approach gives oncologists the information and support they need to prepare a customized, targeted treatment plan for each patient. Nearly 80% of the patients treated at Intermountain Precision Genomics have been connected to targeted drug therapies, which can help lengthen survival in advanced cancer patients without increasing costs.

"Through Navican this approach and all services, including continuous remote access to Intermountain's tumor specialists and treatment navigators, are offered to community hospitals, independent hospital networks and other Integrated Delivery Networks," says Ingo Chakravarty, CEO of Navican. "Patients are based in the community, across the United States and around the world, so should precision medicine, being accessible to all, not just a few."

To this end, Navican will use Philips IntelliSpace Genomics, a comprehensive precision medicine platform built to support the implementation and scaling of informatics-heavy precision medicine programs. Resulting from more than a decade of research and development with clinical partners, it offers integrated workflows with advanced analytic capabilities and clinical decision support by unifying the whole patient picture, and streamlines collaboration across hospitals to support pathologists, oncologists, and researchers. The platform integrates N-of-One’s interpretation capabilities and extensive knowledge-bases providing ready access to a vast amount of available reference literature, guidelines, and evidence further enhancing the platform’s clinical trial matching tools.

"Together with Navican we aim to provide a seamless end-to-end solution using the latest technologies available," says Louis Culot, General Manager Philips Genomics. "Hospitals and health systems will be able to send their patient samples to Navican, for advanced molecular analysis, interpretation and guidance by Intermountain. At the same time they will have access to Intermountain’s advanced services while genome informatics and data flow are fully implemented through Philips IntelliSpace Genomics, and can be further integrated with local EMR and lab systems."

The "turnkey" precision medicine solution will first be made available within the Intermountain Healthcare network. Availability to other hospitals and healthcare systems worldwide is expected second half of 2017. The solution will be presented at Philips booth #5107 and Intermountain's booth #3123 at the American Society of Clinical Oncology Annual Meeting (ASCO) taking place 2 - 6 June in Chicago U.S.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 70,000 employees with sales and services in more than 100 countries.

About Navican
NAVICAN, an Intermountain Healthcare company, offers Precision Cancer CareTM to transform and advance cancer care for patients everywhere that advanced therapies are available. Navican offers expert therapy recommendations and experienced navigators to help patients and their caregivers get the precision therapy they need as soon as possible. Navican uses TheraMapTM, a comprehensive end-to-end service to help oncologists and patients harness the power of precision medicine to improve outcomes and reduce cost. Developed through years of experience and clinical best practices of Intermountain Healthcare, TheraMapTM combines state-of-the-art next generation sequencing technology, clinical expertise and a molecular tumor board to provide a treatment recommendation.

Most Popular Now

Zebra Announces Regulatory Approval of i…

Zebra Medical Vision, the leading machine learning imaging analytics company, announces that the company has been granted the CE approval and subsequent release of its Deep Learning Analytics Engine in...

Mind-Controlled Device Helps Stroke Pati…

Stroke patients who learned to use their minds to open and close a device fitted over their paralyzed hands gained some control over their hands, according to a new study...

Philips and Illumina Team Up with Navica…

Royal Philips (NYSE: PHG, AEX: PHIA) and Navican, an Intermountain Healthcare company, today signed an agreement to deploy a precision health informatics solution that will allow hospitals and health systems...

NHS Organisations to Access IMS MAXIMS C…

Award-winning electronic patient record (EPR) provider IMS MAXIMS has announced the availability of its cloud services on the latest iteration of the UK Government's G Cloud Framework. NHS organisations looking...

Boehringer Ingelheim Builds Digital Lab …

With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together...

Artificial Intelligence to Assist in the…

The University of Tampere and TAYS (Tampere University Hospital) Heart Hospital use artificial intelligence (A.I.) technologies developed by VTT Technical Research Centre of Finland in the home care of heart...

Anyone can Become More Curious. Is that …

Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious". Driven by the company’s curiosity initiative, which measured and described...

EC Open Call FETOPEN-01-2016-2017: FET-O…

The successful exploration of new foundations for radically new future technologies requires supporting a large set of early stage, high risk visionary science and technology projects to investigate new ideas...

Home Monitoring of Blood Sugar Did Not I…

Self-monitoring of blood glucose levels in patients with type 2 diabetes who are not treated with insulin did not improve glycemic control or health-related quality of life after one year...

Call for Applications: 2017 Lyfebulb-Nov…

For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives...

New Cellular Imaging Paves Way for Cance…

Researchers at the Universities of York and Leiden have pioneered a technique which uses florescent imaging to track the actions of key enzymes in cancer, genetic disorders and kidney disease...

UK PACS Win for Carestream Announced

West Hertfordshire Hospitals NHS Trust (West Herts) located in the South East of the UK and Carestream have signed and exchanged contracts to replace the Trust's existing PACS with a...